Herein, we present the results of a multi‐centre retrospective study on the effectiveness of initiating OW semaglutide in patients previously treated with insulin, providing fresh insights into the opportunity of re‐positioning patients with T2D according to the modern therapeutic algorithm. The gene discussed is INS; the disease is type 2 diabetes mellitus.